FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079183054> ?p ?o ?g. }

• W2079183054 abstract "Anti-malarial regimens containing sulphonamide or artemisinin ingredients are widely used in malaria-endemic countries. However, evidence of the incidence of adverse drug reactions (ADR) to these drugs is limited, especially in Africa, and there is a complete absence of information on the economic burden such ADR place on patients. This study aimed to document ADR incidence and associated household costs in three high malaria transmission districts in rural Tanzania covered by demographic surveillance systems.Active and passive surveillance methods were used to identify ADR from sulphadoxine-pyrimethamine (SP) and artemisinin (AS) use. ADR were identified by trained clinicians at health facilities (passive surveillance) and through cross-sectional household surveys (active surveillance). Potential cases were followed up at home, where a complete history and physical examination was undertaken, and household cost data collected. Patients were classified as having 'possible' or 'probable' ADR by a physician.A total of 95 suspected ADR were identified during a two-year period, of which 79 were traced, and 67 reported use of SP and/or AS prior to ADR onset. Thirty-four cases were classified as 'probable' and 33 as 'possible' ADRs. Most (53) cases were associated with SP monotherapy, 13 with the AS/SP combination (available in one of the two areas only), and one with AS monotherapy. Annual ADR incidence per 100,000 exposures was estimated based on 'probable' ADR only at 5.6 for AS/SP in combination, and 25.0 and 11.6 for SP monotherapy. Median ADR treatment costs per episode ranged from US$2.23 for those making a single provider visit to US$146.93 for patients with four visits. Seventy-three per cent of patients used out-of-pocket funds or sold part of their farm harvests to pay for treatment, and 19% borrowed money.Both passive and active surveillance methods proved feasible methods for anti-malarial ADR surveillance, with active surveillance being an important complement to facility-based surveillance, given the widespread practice of self-medication. Household costs associated with ADR treatment were high and potentially catastrophic. Efforts should be made to both improve pharmacovigilance across Africa and to identify strategies to reduce the economic burden endured by households suffering from ADR." @default.
• W2079183054 created "2016-06-24" @default.
• W2079183054 creator A5003597451 @default.
• W2079183054 creator A5008172234 @default.
• W2079183054 creator A5017212396 @default.
• W2079183054 creator A5026823453 @default.
• W2079183054 creator A5026911375 @default.
• W2079183054 creator A5050876898 @default.
• W2079183054 creator A5061193662 @default.
• W2079183054 creator A5067102105 @default.
• W2079183054 creator A5080121371 @default.
• W2079183054 creator A5080273761 @default.
• W2079183054 date "2013-07-11" @default.
• W2079183054 modified "2023-10-14" @default.
• W2079183054 title "Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania" @default.
• W2079183054 cites W1540254559 @default.
• W2079183054 cites W1541226626 @default.
• W2079183054 cites W1812263859 @default.
• W2079183054 cites W1822913646 @default.
• W2079183054 cites W1845088392 @default.
• W2079183054 cites W1990358034 @default.
• W2079183054 cites W1992733039 @default.
• W2079183054 cites W1998409551 @default.
• W2079183054 cites W2008986700 @default.
• W2079183054 cites W2012178015 @default.
• W2079183054 cites W2035283978 @default.
• W2079183054 cites W2045936441 @default.
• W2079183054 cites W2050832165 @default.
• W2079183054 cites W2053040393 @default.
• W2079183054 cites W2055574485 @default.
• W2079183054 cites W20802112 @default.
• W2079183054 cites W2082413458 @default.
• W2079183054 cites W2089006774 @default.
• W2079183054 cites W2090888322 @default.
• W2079183054 cites W2094802120 @default.
• W2079183054 cites W2111868164 @default.
• W2079183054 cites W2112251156 @default.
• W2079183054 cites W2116122577 @default.
• W2079183054 cites W2121734158 @default.
• W2079183054 cites W2125849337 @default.
• W2079183054 cites W2126583499 @default.
• W2079183054 cites W2130249510 @default.
• W2079183054 cites W2133775372 @default.
• W2079183054 cites W2135192999 @default.
• W2079183054 cites W2139048806 @default.
• W2079183054 cites W2156022611 @default.
• W2079183054 cites W2165789743 @default.
• W2079183054 cites W2188296303 @default.
• W2079183054 cites W2463443112 @default.
• W2079183054 cites W2974971472 @default.
• W2079183054 cites W3122758023 @default.
• W2079183054 cites W4252648999 @default.
• W2079183054 doi "https://doi.org/10.1186/1475-2875-12-236" @default.
• W2079183054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3710484" @default.
• W2079183054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23844934" @default.
• W2079183054 hasPublicationYear "2013" @default.
• W2079183054 type Work @default.
• W2079183054 sameAs 2079183054 @default.
• W2079183054 citedByCount "3" @default.
• W2079183054 countsByYear W20791830542014 @default.
• W2079183054 countsByYear W20791830542015 @default.
• W2079183054 countsByYear W20791830542020 @default.
• W2079183054 crossrefType "journal-article" @default.
• W2079183054 hasAuthorship W2079183054A5003597451 @default.
• W2079183054 hasAuthorship W2079183054A5008172234 @default.
• W2079183054 hasAuthorship W2079183054A5017212396 @default.
• W2079183054 hasAuthorship W2079183054A5026823453 @default.
• W2079183054 hasAuthorship W2079183054A5026911375 @default.
• W2079183054 hasAuthorship W2079183054A5050876898 @default.
• W2079183054 hasAuthorship W2079183054A5061193662 @default.
• W2079183054 hasAuthorship W2079183054A5067102105 @default.
• W2079183054 hasAuthorship W2079183054A5080121371 @default.
• W2079183054 hasAuthorship W2079183054A5080273761 @default.
• W2079183054 hasBestOaLocation W20791830541 @default.
• W2079183054 hasConcept C120665830 @default.
• W2079183054 hasConcept C121332964 @default.
• W2079183054 hasConcept C142724271 @default.
• W2079183054 hasConcept C185032368 @default.
• W2079183054 hasConcept C187212893 @default.
• W2079183054 hasConcept C203014093 @default.
• W2079183054 hasConcept C2776120307 @default.
• W2079183054 hasConcept C2778048844 @default.
• W2079183054 hasConcept C2778371730 @default.
• W2079183054 hasConcept C2779357621 @default.
• W2079183054 hasConcept C39432304 @default.
• W2079183054 hasConcept C61511704 @default.
• W2079183054 hasConcept C71924100 @default.
• W2079183054 hasConcept C91375879 @default.
• W2079183054 hasConcept C99454951 @default.
• W2079183054 hasConceptScore W2079183054C120665830 @default.
• W2079183054 hasConceptScore W2079183054C121332964 @default.
• W2079183054 hasConceptScore W2079183054C142724271 @default.
• W2079183054 hasConceptScore W2079183054C185032368 @default.
• W2079183054 hasConceptScore W2079183054C187212893 @default.
• W2079183054 hasConceptScore W2079183054C203014093 @default.
• W2079183054 hasConceptScore W2079183054C2776120307 @default.
• W2079183054 hasConceptScore W2079183054C2778048844 @default.
• W2079183054 hasConceptScore W2079183054C2778371730 @default.
• W2079183054 hasConceptScore W2079183054C2779357621 @default.
• W2079183054 hasConceptScore W2079183054C39432304 @default.

• next